1. Home
  2. VOC vs CGTX Comparison

VOC vs CGTX Comparison

Compare VOC & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VOC

VOC Energy Trust Units of Beneficial Interest

HOLD

Current Price

$2.86

Market Cap

50.7M

Sector

Energy

ML Signal

HOLD

Logo Cognition Therapeutics Inc.

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$1.53

Market Cap

132.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VOC
CGTX
Founded
2010
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.7M
132.4M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
VOC
CGTX
Price
$2.86
$1.53
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$2.88
AVG Volume (30 Days)
53.7K
938.2K
Earning Date
01-01-0001
11-06-2025
Dividend Yield
22.16%
N/A
EPS Growth
N/A
N/A
EPS
0.51
N/A
Revenue
$9,783,812.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$5.58
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.44
$0.22
52 Week High
$5.12
$3.83

Technical Indicators

Market Signals
Indicator
VOC
CGTX
Relative Strength Index (RSI) 43.55 46.12
Support Level $2.82 $1.46
Resistance Level $2.95 $1.61
Average True Range (ATR) 0.08 0.11
MACD -0.01 -0.02
Stochastic Oscillator 3.03 27.03

Price Performance

Historical Comparison
VOC
CGTX

About VOC VOC Energy Trust Units of Beneficial Interest

VOC Energy Trust is a statutory trust. It is created to acquire and hold a term net profits interest for the benefit of the Trust unitholders. The underlying properties include VOC Brazos' net interests which are located in the states of Kansas and Texas. The trust is entitled to receive the net proceeds from the sale of production of oil and natural gas attributable to the underlying properties. The business and affairs of the Trust are managed by the Trustee, and neither VOC Brazos nor any of its affiliates has the ability to manage or influence the operations of the Trust.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Share on Social Networks: